tiprankstipranks
Trending News
More News >
MPH Health Care AG (DE:93M1)
XETRA:93M1

MPH Health Care AG (93M1) AI Stock Analysis

Compare
5 Followers

Top Page

DE:93M1

MPH Health Care AG

(XETRA:93M1)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
€28.00
▲(17.65% Upside)
The stock score is primarily driven by strong technical indicators and solid financial performance, despite valuation concerns due to a negative P/E ratio. The attractive dividend yield partially offsets these valuation issues. The absence of earnings call data and corporate events means these factors did not influence the score.
Positive Factors
Business Model Strength
The diversified revenue streams from medical devices, software, and pharmaceuticals provide a stable income base, reducing dependency on any single product line and enhancing resilience against market fluctuations.
Financial Stability
A strong balance sheet with low leverage and high equity ratio ensures financial stability, providing the company with flexibility to invest in growth opportunities and weather economic downturns.
Profitability Metrics
Strong profitability metrics, including a solid gross profit margin, indicate effective cost management and the ability to maintain healthy margins, supporting long-term financial health.
Negative Factors
Revenue Fluctuations
Significant revenue fluctuations can undermine financial predictability and planning, potentially impacting investment in R&D and strategic initiatives necessary for sustained growth.
Cash Flow Volatility
Volatile cash flows can challenge the company's ability to fund operations and growth initiatives consistently, necessitating improved cash management to align with net income.
Earnings Instability
Negative earnings per share suggest challenges in achieving consistent profitability, which may affect investor confidence and the ability to raise capital for future growth.

MPH Health Care AG (93M1) vs. iShares MSCI Germany ETF (EWG)

MPH Health Care AG Business Overview & Revenue Model

Company DescriptionMPH Health Care AG (93M1) is a leading healthcare company focused on the development, manufacturing, and distribution of innovative medical products and services. Operating primarily in the health technology and pharmaceuticals sectors, MPH Health Care AG specializes in creating solutions that enhance patient care and improve healthcare outcomes. The company's core offerings include medical devices, health management software, and pharmaceutical products aimed at various therapeutic areas.
How the Company Makes MoneyMPH Health Care AG generates revenue through multiple streams, primarily from the sale of its medical devices and health management software. The company partners with hospitals, clinics, and healthcare providers to supply its products, often entering long-term contracts that ensure a steady flow of income. Additionally, MPH Health Care AG earns revenue from its pharmaceutical division by marketing and distributing proprietary drugs, which are often developed in collaboration with research institutions. Strategic partnerships with other healthcare entities and participation in government health programs also contribute to the company's financial performance, allowing it to expand its market reach and enhance product development capabilities.

MPH Health Care AG Financial Statement Overview

Summary
MPH Health Care AG demonstrates strong profitability and financial stability, with a solid equity position and effective cost management. However, revenue fluctuations and cash flow volatility are areas of concern.
Income Statement
78
Positive
MPH Health Care AG has shown improvement in key profitability metrics over recent years. The gross profit margin is strong, and there is a consistent net profit margin indicating profitability. However, revenue has fluctuated significantly, with a notable decline in 2024. Despite these fluctuations, EBIT and EBITDA margins remain healthy, reflecting effective cost management.
Balance Sheet
85
Very Positive
The company's balance sheet is robust, with a high equity ratio and a low debt-to-equity ratio, indicating financial stability. The return on equity is impressive, reflecting efficient use of shareholder funds. The company has managed its liabilities well, maintaining a solid stockholders' equity position, which suggests strong financial health.
Cash Flow
72
Positive
Cash flow analysis reveals some concerns, particularly with operating cash flow being negative in recent years, although it has turned positive in the latest period. The free cash flow shows significant volatility, but recent improvements in free cash flow growth are positive. The ratios indicate a need for better alignment of cash flow generation with net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue-72.59M6.11M7.24M6.85M4.36M-9.02M
Gross Profit-72.59M6.11M125.94M6.80M4.01M-9.45M
EBITDA-37.87M33.32M30.36M29.68M-9.05M-71.00M
Net Income-115.23M32.04M29.54M29.11M-8.96M-70.38M
Balance Sheet
Total Assets218.84M291.06M266.35M236.99M198.00M210.71M
Cash, Cash Equivalents and Short-Term Investments2.65M1.20M5.10M3.82M4.44M4.23M
Total Debt11.72M10.56M13.05M12.99M4.05M7.62M
Total Liabilities13.72M13.19M15.39M15.57M5.69M9.45M
Stockholders Equity205.12M277.87M250.97M221.42M192.31M201.26M
Cash Flow
Free Cash Flow1.02M1.83M-2.02M-170.41K-1.28M-3.36M
Operating Cash Flow3.59M1.83M-2.02M-164.79K-1.28M-3.36M
Investing Cash Flow4.10M3.40M5.40M-8.96M6.37M12.83M
Financing Cash Flow-6.85M-7.70M7.74M-3.02M-3.61M-10.90M

MPH Health Care AG Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price23.80
Price Trends
50DMA
20.46
Positive
100DMA
19.23
Positive
200DMA
19.79
Positive
Market Momentum
MACD
1.02
Positive
RSI
49.13
Neutral
STOCH
7.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:93M1, the sentiment is Neutral. The current price of 23.8 is below the 20-day moving average (MA) of 23.84, above the 50-day MA of 20.46, and above the 200-day MA of 19.79, indicating a neutral trend. The MACD of 1.02 indicates Positive momentum. The RSI at 49.13 is Neutral, neither overbought nor oversold. The STOCH value of 7.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:93M1.

MPH Health Care AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€396.00M20.3552.68%0.15%15.20%6.77%
73
Outperform
€103.20M21.9423.66%0.21%7.53%
70
Outperform
€96.76M-0.84-43.43%5.31%180.19%-196.45%
68
Neutral
€56.88M9.7715.57%6.36%8.24%140.53%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
58
Neutral
€93.50M139.952.09%27.42%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:93M1
MPH Health Care AG
22.60
1.19
5.56%
DE:APPH
APONTIS PHARMA AG
11.00
0.95
9.45%
DE:LIK
Limes Schlosskliniken AG
344.00
14.00
4.24%
DE:HAEK
HAEMATO AG
8.70
-3.65
-29.55%
DE:AJ91
DocCheck AG
11.30
3.61
46.94%
DE:PSG
PharmaSGP Holding SE
33.00
8.64
35.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 13, 2025